---
title: "Releasing the Brake: RCSI's RNA-Activated Implant for Spinal Cord Repair"
pubDate: 2026-02-19
executiveSummary: "In February 2026, the Royal College of Surgeons in Ireland (RCSI) unveiled an 'RNA-activated implant' designed to physically bridge spinal cord injuries while delivering genetic scissors. This bioengineered scaffold silences the biological 'parking brake' in adult neurons, tricking them into an embryonic state of active regrowth."
---

## The History

The current breakthrough at RCSI is the culmination of a decade-long evolution within the Tissue Engineering Research Group (TERG). In the early 2010s, the lab pioneered advanced collagen scaffolds for bone repair, successfully commercializing them. By 2019, they shifted their focus from passive structural supports to "gene-activated" platforms, using biomaterials as localized reservoirs for gene therapy. A strategic pivot toward spinal cord injury accelerated in 2022 with a formal Patient and Public Involvement (PPI) panel ensuring alignment with actual patient priorities. This multi-track research culminated in February 2026 with a landmark publication detailing the RNA-activated implant.

## Key People

* **Prof. Fergal O'Brien**: Leader of the Tissue Engineering Research Group (TERG) who spearheaded the transition from bone scaffolds to neural implants.
* **Dr. Tara McGuire**: Lead researcher on the February 2026 RNA-activated implant study published in Bioactive Materials.
* **Dr. Ian Woods & Liam Leahy**: Leaders of the parallel biophysical approach, engineering 3D-printed electroconductive MXene implants.

## The Story

When an individual suffers a severe spinal cord injury, the communication cables are severed, but unlike a cut on the skin, the central nervous system actively resists repair. Shortly after embryonic development, adult nerve cells activate a specific gene called PTEN, which acts as a chemical "parking brake" that permanently shuts down the ability to grow new extensions. Following trauma, this parking brake stays locked, rendering the severed nerves dormant. RCSI's innovation acts as both a physical bridge and a microscopic pharmacy to physically overcome this biological barrier without triggering an adverse immune response.

## Deep Dive: The Research & Mechanism

The RCSI intervention elegantly combines structural scaffolding with non-viral gene therapy to promote regrowth.

* **The Physical Bridge (Biomimetic Matrix):** The foundation is a highly porous hydrogel mimicking the native spinal cord. Made largely of hyaluronic acid and enriched with collagen type-IV and fibronectin, the matrix physically supports nerve adhesion and calms surrounding inflammatory cells.
* **The Payload (PTEN-siRNA):** Inside this gel are millions of particles carrying small interfering RNA (siRNA). These act as molecular scissors that seek out and destroy the instructions for the PTEN gene. By silencing PTEN, the neuron is tricked into returning to a youthful, embryonic state, prompting aggressive axon sprouting.
* **The Trojan Horse (GET Peptides):** Getting genetic material like siRNA into cells is notoriously difficult. Instead of using risky viral vectors, RCSI employs a synthetic, non-viral vector called the GET peptide. It acts as a molecular shuttle, slipping the payload past the cell membrane and safely releasing the scissors into the cytoplasm before the cell can destroy them.
* **Current Status:** As of February 2026, this intervention remains strictly in the preclinical *in vitro* (laboratory cell model) phase. It has successfully demonstrated robust nerve outgrowth in laboratory models, but it will require in vivo animal safety testing to evaluate its performance against the hostility of a living glial scar before human trials can be considered.

## Sources & References

* **Bioactive Materials Journal (2026)**: [https://pmc.ncbi.nlm.nih.gov/articles/PMC12908063/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12908063/)
    * *The primary peer-reviewed publication detailing the development and in vitro success of the PTEN-siRNA activated scaffold to promote axonal regrowth.*

* **RCSI Official News Release (Feb 2026)**: [https://www.rcsi.com/dublin/news-and-events/news/news-article/2026/02/rcsi-researchers-develop-rna-activated-implant-to-stimulate-nerve-regrowth-after-spinal-cord-injury](https://www.rcsi.com/dublin/news-and-events/news/news-article/2026/02/rcsi-researchers-develop-rna-activated-implant-to-stimulate-nerve-regrowth-after-spinal-cord-injury)
    * *Official university announcement confirming the laboratory model focus and the intention to transition to in vivo testing.*

* **Advanced Science / RCSI News (July 2025)**: [https://www.rcsi.com/dublin/news-and-events/news/news-article/2025/07/rcsi-researchers-develop-3d-printed-implant-to-help-repair-spinal-cord-injuries](https://www.rcsi.com/dublin/news-and-events/news/news-article/2025/07/rcsi-researchers-develop-3d-printed-implant-to-help-repair-spinal-cord-injuries)
    * *Details on the parallel biophysical approach featuring 3D-printed electroconductive MXene implants.*

* **Health Expectations Journal (2024)**: [https://pubmed.ncbi.nlm.nih.gov/39102667/](https://pubmed.ncbi.nlm.nih.gov/39102667/)
    * *Research detailing RCSI's integration of a Patient and Public Involvement (PPI) panel to ensure interventions align with patient priorities.*

* **TERMIS-EU Conference Abstract (2023)**: [https://eu2023.termis.org/wp-content/uploads/2023/03/TERMIS-2023-Abstract-e-Book.pdf](https://eu2023.termis.org/wp-content/uploads/2023/03/TERMIS-2023-Abstract-e-Book.pdf)
    * *Early data detailing the bioinformatic selection of the PTEN/mTOR pathway and the initial delivery of siRNA via GET peptides.*

* **ACS Omega (2023)**: [https://pubs.acs.org/doi/10.1021/acsomega.3c09306](https://pubs.acs.org/doi/10.1021/acsomega.3c09306)
    * *Technical publication exploring the design modifications of the non-viral GET peptide used as the safe "Trojan Horse" delivery system.*
